FGF-16 Antibody (C-2): sc-376214

FGF-16 Antibody (C-2) is a mouse monoclonal IgG2b antibody that detects fibroblast growth factor 16 (FGF-16) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). FGF-16 is a member of the fibroblast growth factor (FGF) family, which plays a crucial role in various biological processes, including cell proliferation, differentiation, and survival. FGF-16 is primarily expressed in the heart and brain, where FGF-16 is involved in the development and maintenance of the cardiovascular and nervous systems. Such localization in these tissues suggests a role in neuroprotection and cardiac function, making FGF-16 a potential target for therapeutic interventions in heart disease and neurodegenerative disorders. FGF-16 interacts with specific fibroblast growth factor receptors (FGFRs), which are essential for mediating biological effects, and understanding these interactions can provide insights into the signaling pathways that regulate cellular responses in health and disease. Anti-FGF-16 antibody (C-2) is an invaluable tool for researchers investigating the complex roles of FGF-16 in various physiological and pathological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

FGF-16 Antibody (C-2) References:

1. Secretion of FGF-16 requires an uncleaved bipartite signal sequence.  |  Miyakawa, K. and Imamura, T. 2003. J Biol Chem. 278: 35718-24. PMID: 12851399
2. FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development.  |  Lu, SY., et al. 2008. Am J Physiol Cell Physiol. 294: C1242-9. PMID: 18337564
3. FGF-16 is required for embryonic heart development.  |  Lu, SY., et al. 2008. Biochem Biophys Res Commun. 373: 270-4. PMID: 18565327
4. FGF-16 is a target for adrenergic stimulation through NF-kappaB activation in postnatal cardiac cells and adult mouse heart.  |  Sofronescu, AG., et al. 2010. Cardiovasc Res. 87: 102-10. PMID: 20097674
5. FGF-2 and FGF-16 protect isolated perfused mouse hearts from acute doxorubicin-induced contractile dysfunction.  |  Sontag, DP., et al. 2013. Cardiovasc Toxicol. 13: 244-53. PMID: 23430353
6. Heart-specific expression of FGF-16 and a potential role in postnatal cardioprotection.  |  Wang, J., et al. 2015. Cytokine Growth Factor Rev. 26: 59-66. PMID: 25106133
7. Expression of the Cardiac Maintenance and Survival Factor FGF-16 Gene Is Regulated by Csx/Nkx2.5 and Is an Early Target of Doxorubicin Cardiotoxicity.  |  Wang, J., et al. 2017. DNA Cell Biol. 36: 117-126. PMID: 27929351
8. FGF-16 protects against adverse cardiac remodeling in the infarct diabetic heart.  |  Hu, Y., et al. 2017. Am J Transl Res. 9: 1630-1640. PMID: 28469770
9. Cardiac Fgf-16 Expression Supports Cardiomyocyte Survival and Increases Resistance to Doxorubicin Cytotoxicity.  |  Wang, J., et al. 2018. DNA Cell Biol. 37: 866-877. PMID: 30230915
10. Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family.  |  Miyake, A., et al. 1998. Biochem Biophys Res Commun. 243: 148-52. PMID: 9473496

The preferred FGF-9 antibody is FGF-9 Antibody (D-8): sc-8413.